Latin America Non-Invasive Prenatal Testing Market

Latin America Non-Invasive Prenatal Testing Market Size (2023 to 2028)

The size of the Latin American non-invasive prenatal testing market was valued at USD 0.32 Billion in 2023. It is further projected to be growing at a CAGR of 11.3% and worth USD 0.55 Billion by 2028.

The term "maternal age" refers to a woman's age at the time of delivery. Increasing maternal age can lead to a variety of health issues, including decreased fertility, high blood pressure, and a higher chance of miscarriage, stillbirths, and maternal mortality. Furthermore, as a result of faulty chromosomal division, maternal age can raise the incidence of genetic abnormalities in newborns. Microcephaly, a short neck, upward slanted eyes, weak muscular tone, and heart, gut, and breathing difficulties are some of the anomalies that can occur in neonates. According to the findings, there has been an increase in maternal advanced age, which is likely to lead to more health difficulties.

In pregnant mothers, early diagnosis of genetic disorders caused by aberrant chromosomal division is becoming increasingly critical. DNA in maternal plasma/foetal cells in maternal blood can also be detected through non-invasive prenatal testing. NIPT testing will become more important in Latin America as maternal age and the incidence of chromosomal problems rise. Increased healthcare infrastructure, rising public healthcare spending, the presence of a large patient population, and the expanding availability of contemporary healthcare technologies are a few of the key factors driving the non-invasive prenatal testing market in the Latin American region.

A variety of factors influence the amount of foetal fraction in the blood. One such factor is maternal weight, which has a considerable impact on the amount of foetal fraction in maternal blood. Because obese women's plasma contains little amounts of foetal DNA, it may not yield accurate results when testing for trisomy and other abnormalities. As a result, patients who weigh more than 250 pounds may have inconclusive results (Source: Non-invasive Prenatal Testing Services to Change for Texas Medicaid, March 2016). This makes NIPT ineffective for detecting chromosomal abnormalities in obese women. Furthermore, positive NIPT results may necessitate a confirmation test using invasive techniques like as amniocentesis and CVS.

This research report on the Latin America non-invasive prenatal testing market has been segmented and sub-segmented into the following categories.

By Instruments: 

• Ultrasound
• NGS
• PCR
• Microarray

By Method: 

• FCMB
• Cf-DNA

By Application: 

• Trisomy
• Microdeletion
• Genetics
• Rh Factor

By End User: 

• Hospitals
• Diagnostic Labs

By Country: 

• Mexico
• Brazil
• Argentina
• Chile
• Rest of Latin America

Geographically, the Latin American region is predicted to record a healthy CAGR during the forecast period due to the factors such as the high prevalence of genetic disorders across a large population base, growing awareness about genetic abnormalities, technological advancements, and customer preference for non-invasive techniques over invasive techniques. One of the market's significant limitations is the lack of clinical validity of non-invasive prenatal testing results.

Several laboratories and corporations have struck distribution partnerships with test providers in order to give advanced products and services to patients, which is further expected to encourage the market growth in this region during the forecast period. Key market players can expect considerable development prospects in emerging countries such as Brazil and Mexico in the next years.

The Brazilian market is forecasted to dominate the Latin American Non-Invasive Prenatal Testing Market throughout the forecast period. Obstetricians are increasingly promoting non-invasive testing as an alternative to invasive procedures and for initial diagnostic screening during pregnancy. Argentina leads the Non-Invasive Prenatal Testing Market in Latin America, followed by Brazil. This region's market growth is being driven by quickly expanding healthcare infrastructure, awareness programmes and conferences, and the growing attention of prominent players to expand their footprint.

KEY MARKET PLAYERS:

Companies playing a key role in the Latin America non-invasive prenatal testing market profiled in the report are GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).